Development of Argatroban, a Direct Thrombin Inhibitor, and Its Clinical Application
Development of Argatroban, a Direct Thrombin Inhibitor, and Its Clinical Application
复制标题
直接凝血酶抑制剂阿加曲班的研制及其临床应用
DOI：
10.1055/s-2007-996129
复制
发表时间：
1997
影响因子：
5.7
通讯作者：
K. Kario
中科院分区：
文献类型：
--
作者：
T. Matsuo;M. Koide;K. Kario
Argatroban, a direct thrombin inhibitor, is used clinically because of its safe and effective antithrombotic action. This drug of low molecular weight shows reversible inhibition of thrombin irrespective of whether thrombin is fibrin-bound or soluble. Optimal anticoagulant effects can easily be attained by monitoring with the activated partial thromboplastin time or whole-blood activated clotting time when a therapeutic range of argatroban equivalent to that of heparin is used. The antithrombotic action is simply detected with a chromogenic substrate assay. The clinical use of the drug in Japan was approved for the treatment of chronic peripheral arterial obstructive disease and acute ischemic stroke. For coronary artery disease in patients with deficiency of antithrombin activities attributable to either antithrombin III or heparin cofactor II deficiency, argatroban is effective as an anticoagulant. Acute coronary occlusion during and after percutaneous transluminal coronary angioplasty can be treated by argatroban as an alternative to heparin. The presence of platelets activated by a trace amount of thrombin is evidenced by modified methods of platelet aggregometry in acute ischemic stroke. Therefore, argatroban can render the platelets insensitive against the platelet hyperaggregation enhanced by thrombin.
